Organon & Co. (NYSE:OGN) Shares Acquired by Teachers Retirement System of The State of Kentucky

Teachers Retirement System of The State of Kentucky grew its stake in shares of Organon & Co. (NYSE:OGN) by 250.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 80,128 shares of the company’s stock after acquiring an additional 57,255 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in Organon & Co. were worth $1,155,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Fruth Investment Management increased its stake in Organon & Co. by 1.9% during the 4th quarter. Fruth Investment Management now owns 37,040 shares of the company’s stock valued at $534,000 after purchasing an additional 700 shares in the last quarter. Gladius Capital Management LP grew its holdings in shares of Organon & Co. by 65.1% during the fourth quarter. Gladius Capital Management LP now owns 2,176 shares of the company’s stock valued at $31,000 after buying an additional 858 shares during the last quarter. Raymond James Trust N.A. increased its position in shares of Organon & Co. by 7.6% in the 4th quarter. Raymond James Trust N.A. now owns 13,868 shares of the company’s stock valued at $200,000 after acquiring an additional 983 shares during the period. CWM LLC raised its stake in Organon & Co. by 8.3% in the 4th quarter. CWM LLC now owns 14,217 shares of the company’s stock worth $205,000 after acquiring an additional 1,087 shares during the last quarter. Finally, Allworth Financial LP lifted its position in Organon & Co. by 68.8% during the 4th quarter. Allworth Financial LP now owns 3,136 shares of the company’s stock worth $45,000 after acquiring an additional 1,278 shares during the period. 77.43% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Piper Sandler raised their price objective on Organon & Co. from $22.00 to $24.00 and gave the stock an “overweight” rating in a research note on Monday, April 29th. The Goldman Sachs Group increased their price target on shares of Organon & Co. from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Friday, May 3rd.

Organon & Co. Stock Performance

Shares of OGN stock opened at $20.84 on Monday. Organon & Co. has a 52-week low of $10.84 and a 52-week high of $24.08. The company has a quick ratio of 1.15, a current ratio of 1.65 and a debt-to-equity ratio of 181.35. The stock has a market cap of $5.36 billion, a PE ratio of 5.10, a price-to-earnings-growth ratio of 0.89 and a beta of 0.87. The business has a 50-day simple moving average of $20.17 and a 200-day simple moving average of $17.80.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings results on Thursday, May 2nd. The company reported $1.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.83 by $0.31. The company had revenue of $1.62 billion during the quarter, compared to the consensus estimate of $1.57 billion. Organon & Co. had a negative return on equity of 360.57% and a net margin of 16.50%. On average, equities analysts expect that Organon & Co. will post 4.3 EPS for the current year.

Organon & Co. Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, June 13th. Investors of record on Monday, May 13th were given a dividend of $0.28 per share. The ex-dividend date of this dividend was Friday, May 10th. This represents a $1.12 annualized dividend and a yield of 5.37%. Organon & Co.’s dividend payout ratio is presently 27.38%.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.